Murine Models of Obesity-Related Cancer Risk

Lukmon M Raji; Monowarul M Siddique; Margaret S Bohm; Joseph F Pierre; Mary C Playdon; Scott A Summers; Bing Li; Katherine L Cook; E Angela Murphy; Liza Makowski

doi:10.1158/1940-6207.CAPR-24-0545

Back

Murine Models of Obesity-Related Cancer Risk

Journal article

Open access

Peer reviewed

Murine Models of Obesity-Related Cancer Risk

Lukmon M Raji, Monowarul M Siddique, Margaret S Bohm, Joseph F Pierre, Mary C Playdon, Scott A Summers, Bing Li, Katherine L Cook, E Angela Murphy and Liza Makowski

Cancer prevention research (Philadelphia, Pa.), Vol.18(9), pp.509-529

09/02/2025

DOI: 10.1158/1940-6207.CAPR-24-0545

PMCID: PMC12289351

PMID: 40509936

Files and links (1)

url

https://doi.org/10.1158/1940-6207.CAPR-24-0545View

Published (Version of record) Open Access

Abstract

Obesity is a global menace that has impacted over 14% of adults worldwide and over a third of Americans. Importantly, obesity is associated with an increased risk of over 13 types of cancer and worse outcomes, including increased mortality. This review focuses on the importance of considering obesity and metabolic dysfunction in cancer risk as part of the National Cancer Institute's funded consortium known as the Metabolic Dysfunction and Cancer Risk Program (MeDOC). It describes previous and ongoing mouse models used in studies conducted by MeDOC consortium members, as well as other relevant studies. Most cancer studies examine tumor progression, metastasis, or recurrence, which are consequences following tumor onset; however, this approach does not consider risk per se. To truly model cancer risk, parameters to measure include the quantification of cancer onset, measured as incidence or latency. Investigators must be cognizant of many factors in study design, including the choice of cancer model and genetic strain. Preclinical approaches addressing risk typically include genetically engineered mouse models or the administration of irritants or carcinogens. We also discuss the transplantation of cells or tumors such as allografts or xenografts, with a focus on tumor rejection or regression to approximate cancer risk, not cancer progression. Herein, we highlight two cancers, breast and colorectal cancer, where risk is associated with obesity and discussed varied murine model approaches, as well as key findings that explore cancer risk, prevention, or interception.

Details

Title: Subtitle: Murine Models of Obesity-Related Cancer Risk
Creators: Lukmon M Raji - University of Tennessee Health Science Center
Monowarul M Siddique - University of Utah
Margaret S Bohm - University of Tennessee Health Science Center
Joseph F Pierre - University of Wisconsin–Madison
Mary C Playdon - Huntsman Cancer Institute
Scott A Summers - University of Utah
Bing Li - University of Iowa, iowa city, United States
Katherine L Cook - Wake Forest School of Medicine, Winston Salem, NC, United States
E Angela Murphy - University of South Carolina System
Liza Makowski - University of Tennessee Health Science Center
Resource Type: Journal article
Publication Details: Cancer prevention research (Philadelphia, Pa.), Vol.18(9), pp.509-529
DOI: 10.1158/1940-6207.CAPR-24-0545
PMID: 40509936
PMCID: PMC12289351
NLM abbreviation: Cancer Prev Res (Phila)
ISSN: 1940-6215
eISSN: 1940-6215
Publisher: AMER ASSOC CANCER RESEARCH; PHILADELPHIA
Grant note: National Institutes of Health (NIH): U01CA272541, U01CA272529, U01CA272424, U01CA272977 NCI of the NIHUniversity of Texas Health Science Center for Cancer Research: R01CA253329 NIH/NCI: NCI U01CA272977 NIH: U01CA272529 NCI: BC190271 Department of Defense Breast Cancer Research Program Breakthrough Level 2 Award: R01DK113788 NIH grant NIDDK: R01CA246809 NIH grant NCI
This project is supported by the NCI of the NIH under award numbers U01CA272541, U01CA272529, U01CA272424, and U01CA272977 which is part of the MeDOC consortium. We thank the MeDOC Mouse Working Group and Steering Committee for discussion. We thank the University of Texas Health Science Center for Cancer Research for feedback. Grant support: This work was supported by the following grants to faculty and trainees: NIH/NCI grant R01CA253329 (L. Makowski, J.F. Pierre, and K.L. Cook); NIH grant NCI U01CA272541 (L. Makowski, J.F. Pierre, and K.L. Cook); NCI grant U01CA272529 (M.C. Playdon and S.A. Summers); NIH grants R01CA180986 (B. Li), U01CA272424 (B. Li), R01CA27259 (S.A. Summers), R01DK131609 (S.A. Summers), R01DK116888 (S.A. Summers), R01DK115824 (S.A. Summers), R01HL170575 (S.A. Summers), and R01DK130296 (S.A. Summers); NIH grant F31CA290773 (M.S. Bohm), Mark Foundation for Cancer Research (L. Makowski); Department of Defense Breast Cancer Research Program Breakthrough Level 2 Award BC190271 (K.L. Cook); NIH grant NIDDK R01DK113788 (J.F. Pierre); NIH grant NCI R01CA246809 (E.A. Murphy); and NIH grant NCI U01CA272977 (E.A. Murphy).
Language: English
Electronic publication date: 06/13/2025
Date published: 09/02/2025
Academic Unit: Pathology; Surgery
Record Identifier: 9984829019502771

Metrics

7 Record Views

1 Times Cited - Web of Science